Clinical trials: High Grade Neuroendocrine Cancer
Neuroendocrine Tumors
A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs
This is an open label, single arm, phase II multicentre study designed to evaluate the efficacy and safety of pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib…
- Trial name
- PELICAN (NCT06232564)
- Testing
- Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Imperial College London
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Background: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head.
- Conditions
- Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine, Neuroendocrine; Carcinoma
- Trial name
- NCT06406465
- Testing
- Belinostat, Cisplatin, Etoposide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer, Kidney Cancer
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether giving chemotherapy after surgery is more effective than surgery alone in…
- Conditions
- Endometrial Cancer, Kidney Cancer, Ovarian Cancer, Pheochromocytoma
- Trial name
- NCT00002641
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 45 sites in Austria, Belgium and 11 more
- Volunteers
- 350 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neuroendocrine Tumors
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
The purpose of this research study is to test if pembrolizumab is safe and effective for treating patients with metastatic high-grade neuroendocrine tumors who have failed platinum based chemotherapy.The study drug, pembrolizumab…
- Trial name
- NCT02939651
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Fox Chase Cancer Center
SCLC, Small Cell Cancer
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
Background: Small cell lung cancer (SCLC) and high-grade neuroendocrine cancers (HGNEC) are aggressive neuroendocrine cancers. At first, SCLC and HGNEC respond to chemotherapy.
- Conditions
- SCLC, Small Cell Cancer, Advanced Solid Tumor, High Grade Neuroendocrine Cancers
- Trial name
- NCT04802174
- Testing
- Lurbinectedin, Berzosertib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET).
- Conditions
- Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
- Trial name
- NCT05746208
- Testing
- Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of California, San Francisco
Glioblastoma, High Grade Glioma
Individual Patient Compassionate Use of GX-I7
Compassionate use of GX-I7 for patients with serious life-threatening illness that have exhausted all available therapies, with no other therapy options.
- Conditions
- Glioblastoma, High Grade Glioma, Recurrent Glioblastoma, Melanoma
- Trial name
- NCT04289155
- Testing
- GX-I7
- Where
- South Korea
- Sponsor
- Genexine, Inc.
Small-cell Lung Cancer, Neuroendocrine Carcinoma
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
This is a non-randomized single-arm, two cohorts, phase II study of iadademstat in combination with weekly paclitaxel in patients with relapse/refractory SCLC or extrapulmonary G3 Neuroendocrine Carcinomas.
- Trial name
- NCT05420636
- Testing
- Iadademstat, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Neuroendocrine Neoplasm
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
The 2017 World Health Organization (WHO) introduced a new category of high-grade, well-differentiated neuroendocrine neoplasms (NENs) that called neuroendocrine tumors (NETs) G3 in pancreatic NENs classification and, then, in…
- Trial name
- TAPIOCA (NCT06343428)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- European Institute of Oncology
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
This is a pilot study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinoma
- Trial name
- NCT03136055
- Testing
- Pembrolizumab, Irinotecan, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Neuroendocrine Neoplasms (Tumours)
The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard Therapy
The response rate to second-line or later therapies for extrapulmonary high-grade neuroendocrine neoplasms (NENs) remains low, with no established standard treatment regimen.
- Trial name
- SKB264-II-NEN (NCT07077564)
- Testing
- Sac-TMT
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cancer
Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy
The purpose of the AveNEC trial is to investigate the clinical activity and safety of avelumab in patients with NEC G3 (WHO 2010), including "NET G3" who are progressive after first line chemotherapy.
- Trial name
- AveNEC (NCT03352934)
- Testing
- Avelumab
- Where
- 4 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Johannes Gutenberg University Mainz
Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that develops anywhere other than the lungs. EPNEC is also deadly.
- Conditions
- Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung Carcinoma
- Trial name
- NCT07509034
- Testing
- Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT01076530
- Testing
- vorinostat, temozolomide, diagnostic laboratory biomarker analysis
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Glioma
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors.
- Conditions
- Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT05538130
- Testing
- PF-07799544, PF-07799933
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 148 people
- Sponsor
- Pfizer
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal…
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT02713269
- Testing
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroendocrine Tumor
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
This early phase I trial determines where and to what degree the tracer [68Ga] Ga-FAPI-04 accumulates in normal and cancer tissues in patients with high grade neuroendocrine cancer.
- Trial name
- NCT07132645
- Testing
- Computed Tomography, Gallium Ga 68-DOTA-FAPI-04, Positron Emission Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Michigan Rogel Cancer Center